fig5

Figure 5. Metabolomic profiling reveals limited global divergence but identifies selective metabolic alterations in chemoresistant HR+/HER2- BC cells. (A) Integrated transcriptomic and metabolomic pathway enrichment analysis highlighting dysregulated metabolic pathways in taxane- and anthracycline-resistant models; (B and C) Heatmaps of the top 50 most regulated metabolites in chemoresistant MCF-7 (B) and ZR-75-1 (C) cell models relative to their parental counterparts. Color scale represents log10-transformed intensities. HR+/HER2-: Hormone receptor-positive/human epidermal growth factor receptor 2-negative; BC: breast cancer; NES: normalized enrichment score; Pac-R: paclitaxel-resistant; Epi-R: epirubicin-resistant; Doc-R: docetaxel-resistant.